Scholar Rock
Price & Volume
Stats
See more52W Range | $27.07-$61.76 |
Market Cap | $5.1B |
Shares Short | 22M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | -100% |
Gross Profit (12 Mos) | -$207.4M |
Diluted EPS | -$3.32 |
News
See moreYahoo Finance • 5 days ago
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Yahoo Finance • 28 days ago
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions
Yahoo Finance • 28 days ago
Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy
Yahoo Finance • 29 days ago
Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says
About
CEO | Mr. David L. Hallal |
CFO | Mr. Vikas Sinha C.A., CPA, M.B.A. |
Address | 301 Binney Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 289 |